The Expansion of Bispecifics in Myeloma -What’s Next? Alfred Garfall, MD
Bispecific antibodies are changing the treatment landscape for multiple myeloma, offering new hope for patients who have exhausted other options. In this video, Dr. Alfred Garfall discusses how bispecific therapies are expanding beyond the relapsed and refractory setting, what new targets are being explored, and what the future may hold for earlier use and combination strategies. #Myeloma #BispecificAntibodies #Immunotherapy #MultipleMyeloma #CancerResearch #HealthTree If this video has helped you or a loved one, consider donating to HealthTree. Every donation helps us continue to create free and high-quality blood cancer educational content: https://give.healthtree.org/give/6286... For an organized lesson structure, watch on our site here: https://linktr.ee/HealthTreeUniversity Create a free account to track your progress, bookmark lessons, and keep up-to-date on the latest advancements in treating cancer! Patients have the key to find cures for cancer. Learn more about HealthTree's services here: https://healthtree.org/curehub?utm_so... Educated and empowered patients have better outcomes. We've partnered with hundreds of medical experts and doctors to help you learn more about your disease.
Innovations in Myeloma Therapies: Promise of ADCs, CELMoDs, BCL2 Inhibitors, & SINEs | Dan Vogl, MD
Latest Clinical Data for First-line Maintenance and R/R Small-Cell Lung Cancer (SCLC)
Multiple Myeloma Therapy Evolution - Dr. Joseph Mikhael
The Modern Myeloma Toolbox | Tarek Mouhieddine, MD #myeloma
Expanding Myeloma Treatments: Power of Bispecific & Trispecific Antibodies| Dr. Aravind Ramakrishnan
Resetting Immunity: The Power of CAR-T Therapy with Dr. Carl June @ The Cure JM Family Conference
What do tech pioneers think about the AI revolution? - The Engineers, BBC World Service
Understanding Your Myeloma Labs: What They Mean, What Matters, and When to Ask Questions
More Options, More Hope: The New Reality for Newly Diagnosed Myeloma | Gurbakhash Kaur, MD #myeloma
Your Multiple Myeloma Lab Results, Decoded: What They Mean and What They Don’t
Ascites A to Z by Ethan Weinberg, MD
AFTD Care Partner Learning Series Webinar: Navigating Behavioral Variant FTD Symptoms
Myeloma 101: Understanding Multiple Myeloma, Risk Factors, Diagnosis & Treatments Explained
Introduction to Suture
ISB 2001 in Relapsed/Refractory #Myeloma: Phase 1 Results | Hang Quach, MD, Cyril Konto, MD | #ASH24
Myeloma Philadelphia HealthTree Round Table - Audience Q&A with Faculty
Understanding Multiple Myeloma (Multiple Myeloma Explained Clearly)
Bi-specific and tri-specific T cell engagers for the treatment of myeloma
Relapsed Multiple Myeloma: What Every Patient Needs to Know
